Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.

[1]  Satoru Takahashi,et al.  Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study , 2020, Lower urinary tract symptoms.

[2]  S. Noble,et al.  Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. , 2020, European urology.

[3]  K. McVary,et al.  The Urothelium, the urinary microbioma and men LUTS: a systematic review. , 2020, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[4]  A. Basiri,et al.  Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin – A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder: A Case–Control Study , 2020, Clinical pharmacology : advances and applications.

[5]  Kun-jie Wang,et al.  Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis , 2020, International Urogynecology Journal.

[6]  L. Phillips,et al.  Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex. , 2020, European urology focus.

[7]  D. Staskin,et al.  International Phase III, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. , 2020, The Journal of urology.

[8]  J. Redorta,et al.  Treatment Response and Complications after Intradetrusor Onabotulinumtoxin A Injection in Male Patients with Idiopathic Overactive Bladder Syndrome. , 2020, The Journal of urology.

[9]  H. Kakizaki,et al.  Efficacy of vibegron, a novel β3‐adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo‐controlled, double‐blind, comparative phase 3 study , 2020, BJU international.

[10]  Zhipeng Chen,et al.  The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy , 2020, Medicine.

[11]  E. Solomon,et al.  Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder (OAB). , 2020, Urology.

[12]  B. Schurch,et al.  How can we better manage drug‐resistant OAB/DO? ICI‐RS 2018 , 2019, Neurourology and urodynamics.

[13]  H. Kakizaki,et al.  Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). , 2019, European urology focus.

[14]  R. Dmochowski,et al.  A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. , 2019, European urology.

[15]  S. Noble,et al.  Clinical and Patient-reported Outcome Measures in Men Referred for Consideration of Surgery to Treat Lower Urinary Tract Symptoms: Baseline Results and Diagnostic Findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). , 2019, European urology focus.

[16]  Masashi Kato,et al.  Comparison in the efficacy of fesoterodine or mirabegron add‐on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies , 2019, Neurourology and urodynamics.

[17]  R. Dmochowski,et al.  The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. , 2019, Urology.

[18]  Tom Marcelissen,et al.  The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction , 2019, Neurourology and urodynamics.

[19]  A. Sahai,et al.  Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity. , 2019, Urology.

[20]  D. G. Shin,et al.  Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double‐blind, placebo‐controlled, parallel comparison phase IV study , 2018, Neurourology and urodynamics.

[21]  P. Abrams,et al.  Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). , 2018, European urology.

[22]  E. Deeks.  Mirabegron: A Review in Overactive Bladder Syndrome , 2018, Drugs.

[23]  A. De la taille,et al.  Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction , 2018, Prostate Cancer and Prostatic Diseases.

[24]  P. Bigot,et al.  Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder , 2018, World Journal of Urology.

[25]  C. Liao,et al.  Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. , 2018, Urology.

[26]  Hsiang-Ying Lee,et al.  Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis , 2018, World Journal of Urology.

[27]  J. Boura,et al.  Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men , 2018, International Urology and Nephrology.

[28]  Masashi Kato,et al.  Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic‐based study , 2018, International journal of urology : official journal of the Japanese Urological Association.

[29]  M. Spinelli,et al.  Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature. , 2018, European urology.

[30]  M. Stölzel,et al.  Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. , 2017, European urology focus.

[31]  P. Abrams,et al.  Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study) , 2017, BJU international.

[32]  B. Schurch,et al.  Long‐term compliance and results of intravesical botulinum toxin A injections in male patients , 2017, Neurourology and urodynamics.

[33]  M. Oelke,et al.  Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies , 2017, Therapeutic advances in urology.

[34]  R. Dmochowski,et al.  Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI‐RS 2015) , 2017, Neurourology and urodynamics.

[35]  L. Cardozo,et al.  How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI‐RS 2015—Part 2 , 2017, Neurourology and urodynamics.

[36]  K. Ohba,et al.  The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men , 2016, BMC Urology.

[37]  D. Globe,et al.  Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study , 2016, International Urology and Nephrology.

[38]  P. Grise,et al.  Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms? , 2016, Current opinion in urology.

[39]  Y. Homma,et al.  Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan (MILAI study) , 2015, BJU international.

[40]  L. Cindolo,et al.  The Current Indications and the Benefits of Combining a β3-Agonist with an Anticholinergic for the Treatment of OAB. , 2015, Current drug targets.

[41]  V. Tse,et al.  Botulinum toxin (OnabotulinumtoxinA) in the male non‐neurogenic overactive bladder: clinical and quality of life outcomes , 2015, BJU international.

[42]  Tae Heon Kim,et al.  Effect of Detrusor Overactivity on Functional Outcomes After Holmium Laser Enucleation of the Prostate in Patients With Benign Prostatic Obstruction. , 2015, Urology.

[43]  W. Nahas,et al.  Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate? , 2015, The Journal of urology.

[44]  M. Faraday,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. , 2015, The Journal of urology.

[45]  N. Masumori,et al.  A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. , 2015, The Journal of urology.

[46]  C. Liao,et al.  Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder , 2015 .

[47]  Michelle E Johnson,et al.  Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data , 2015, Current medical research and opinion.

[48]  J. Shim,et al.  Prediction of Persistent Storage Symptoms after Transurethral Resection of the Prostate in Patients with Benign Prostatic Enlargement , 2014, Urologia Internationalis.

[49]  J. Langenhuijsen,et al.  Detrusor overactivity does not predict bothersome storage symptoms after photoselective vaporization of the prostate with lithium triborate laser. , 2014, Urology.

[50]  T. Voets,et al.  TRP channels in lower urinary tract dysfunction , 2014, British journal of pharmacology.

[51]  R. Dmochowski,et al.  Mirabegron for Male Lower Urinary Tract Symptoms , 2013, Current Urology Reports.

[52]  C. Nardo,et al.  OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. , 2013, European urology.

[53]  V. Nitti,et al.  Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies , 2013, International journal of clinical practice.

[54]  T. Kosaka,et al.  β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men , 2013, International Urology and Nephrology.

[55]  C. Fowler,et al.  OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. , 2012, European urology.

[56]  V. Mirone,et al.  Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. , 2011, European urology.

[57]  M. Brin,et al.  Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. , 2011, European urology.

[58]  C. Stief,et al.  The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. , 2011, European urology.

[59]  P. Ellis,et al.  A placebo‐controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder , 2010, BJU international.

[60]  J. J. de la Rosette,et al.  Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. , 2008, European urology.

[61]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[62]  K. Patrick,et al.  Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. , 2006, The Cochrane database of systematic reviews.

[63]  C. Roehrborn,et al.  A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. , 2006, European urology.

[64]  C. De Nunzio,et al.  The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. , 2003, The Journal of urology.

[65]  T. Yamanishi,et al.  Neurourology and Urodynamics , 2020 .

[66]  R. Lombardo,et al.  Metabolic syndrome and smoking are associated with persistence of nocturia after transurethral resection of the prostate , 2019, Neurourology and urodynamics.

[67]  F. Burkhard,et al.  EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. , 2018, European urology.

[68]  F. Bruyère,et al.  A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. , 2016, European urology.

[69]  L. Dell’Atti.  Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients. , 2015, European review for medical and pharmacological sciences.

[70]  S. Kaplan,et al.  Voiding Dysfunction Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS) , 2022 .